zamtocabtagene autoleucel (MB-CART2019.1) Clinical Trials
2 recruitingBiologic
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
B-Cell Neoplasm
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT06508931
Recruiting
Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+5 more
Miltenyi Biomedicine GmbH248 enrolled25 locationsNCT04792489